Citius Oncology, Inc. CTOR Earnings per common share - diluted (in dollars per share)
Earnings per common share - diluted (in dollars per share) at other companies
Other financials
Where this comes from
Reported directly by Citius Oncology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about Citius Oncology, Inc.'s earnings per common share - diluted (in dollars per share).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Citius Oncology, Inc.'s earnings per common share - diluted (in dollars per share)?
- Citius Oncology, Inc. (CTOR) reported earnings per common share - diluted (in dollars per share) of -$0.27 in Q1 2026.
- How has Citius Oncology, Inc.'s earnings per common share - diluted (in dollars per share) changed year-over-year?
- Citius Oncology, Inc.'s earnings per common share - diluted (in dollars per share) decreased by 145.5% year-over-year, from -$0.11 to -$0.27.
- What is the long-term trend for Citius Oncology, Inc.'s earnings per common share - diluted (in dollars per share)?
- Over 2 years (2023 to 2025), Citius Oncology, Inc.'s earnings per common share - diluted (in dollars per share) has grown at a 33.8% compound annual growth rate (CAGR), from -$0.19 to -$0.34.
- What does earnings per common share - diluted (in dollars per share) mean?
- Calculates the portion of a company's profit allocated to each share of common stock, assuming all potentially dilutive securities are converted. This provides a conservative view of shareholder value by accounting for the potential impact of stock options and other equity-based instruments.